Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2020 Aug 4;19(9):1809–1821. doi: 10.1158/1535-7163.MCT-20-0160

Figure 1. Pan-PIM kinase inhibitors reduces leukemia burden in ETP-ALL PDX models.

Figure 1.

(A) Relative mRNA expression of PIM1, PIM2, and PIM3 in T-ALL PDX cells. (B) T-ALL PDX cells were incubated with the AZD1208 or LGB321 (AZD 3μM or LGB 1μM) for 72h and then the percentage of viable cells was quantified by the ATPlite assay. The growth of DMSO control cells was considered 100% and percent cell growth after individual treatment is reported relative to the DMSO. The data shown are the average +/− standard deviation (S.D.) of three independent experiments. (C-E) The PB, spleen, and bone marrow (BM) were harvested and analyzed hCD45+ve cells by flow cytometry. % hCD45+ve data shown are the average +/− S.D. from five samples per treatment. (F) Western blot (WB) analysis of lysates collected from BM cells using the specified antibodies. Each lane on the WB represents an individual tumor.